CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
Phase 1
Berlin, Germany and 1 other location
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that caus...
Phase 2
Berlin, Germany and 74 other locations
to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...
Phase 3
Berlin, Germany and 297 other locations
and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...
Phase 3
Berlin, Germany and 739 other locations
This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resis...
Phase 2
Berlin, Germany and 139 other locations
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...
Phase 3
Berlin, Germany and 177 other locations
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...
Phase 3
Berlin, Germany and 157 other locations
of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/ ...
Phase 3
Berlin, Germany and 765 other locations
performed thus far excluded patients with an eGFR below 25 mL/min/1.73m2 at inclusion, prevalent dialysis patients, and kidney transplant r...
Phase 3
Berlin, Germany and 90 other locations
with end stage kidney disease (ESKD) undergoing maintenance dialysis....
Phase 2, Phase 3
Berlin, Germany and 462 other locations
Clinical trials
Research sites
Resources
Legal